|
|
|
| |
|
|
| |
The latest drug discovery news from News Medical |
|
|
|
| |
 From Insight to Decision with Organ-on-a-chip
Learn from Novo Nordisk, Bristol Myers Squibb, Servier, Jazz Pharmaceuticals, and more at the CN Bio Organ-on-Chip e Symposium, a virtual event taking place on 2 and 8 December.
Join expert-led sessions exploring how human-relevant Organ-on-chip models address challenges across ADME, toxicology, model development, and translational science.
| |
|
|
| |  | | |  DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). | | | | |  The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. | | | | |  Cell Therapies Pty Ltd and S2N.Bio (“S2N”) have commenced technology transfer of S2N’s cell therapy candidate for Alzheimer’s disease. The transfer will enable GMP manufacture of clinical trial material for S2N’s first-in-human study in Australia. | | | | |  The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC). | | | | |  A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation. | | | | |  An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. | | | | |  Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment. | |
|
|
| | | How would you rate today's newsletter?
| |
|
|
| | |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
|
|
